Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now?
Oliver
R T
RT
School of Medicine & Dentistry, St Bartholomew's Hospital, Department of Medical Oncology, West Smithfield, London, UK.
D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D018579:Patient Selection; D015990:Placebo Effect; D015983:Selection Bias; D016896:Treatment Outcome
D016898:Interferon-alpha; D007376:Interleukin-2